Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com

Lipocine (NASDAQ:LPCN) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Trading Down 0.5 %

Lipocine stock opened at $5.08 on Monday. The stock has a market cap of $27.17 million, a price-to-earnings ratio of -2.97 and a beta of 1.22. The company’s 50-day moving average price is $4.27 and its two-hundred day moving average price is $5.59. Lipocine has a 52 week low of $2.31 and a 52 week high of $11.79.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $0.09 million for the quarter. Research analysts expect that Lipocine will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.